X
Xiong Cai
Researcher at Millennium Pharmaceuticals
Publications - 9
Citations - 165
Xiong Cai is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Receptor antagonist & Histamine receptor. The author has an hindex of 7, co-authored 9 publications receiving 164 citations.
Papers
More filters
Patent
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
TL;DR: In this article, 2,5-Diaryl tetrahydrofurans, 1,3-diaryl cyclopentanes, and 2.5-dimethyltetrahydrothiophenes (2.5d) were shown to reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response.
Patent
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
TL;DR: In this article, 2,5-Diaryl tetrahydrofurans, 1,3-diaryl cyclopentanes, 2,4-direl pyrrolidines, and 2.5-dimethyltetrahydrothiophenes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response.
Journal ArticleDOI
Synthesis of CMI-977, a Potent 5-Lipoxygenase Inhibitor†
Xiong Cai,Mukund S. Chorghade,Aberra Fura,Gurmit S. Grewal,Karen A. Jauregui,Heather A. Lounsbury,Ralph Scannell,C. Grace Yeh,and Michelle A. Young,Shaoxia Yu,Liang Guo,Robert M. Moriarty,Raju Penmasta,Munagala S. Rao,Rajesh K. Singhal,Zhengzhe Song,James P. Staszewski,and Sudersan M. Tuladhar,Sanmin Yang +18 more
TL;DR: In this article, the S,S isomer was found to have the best biological activity and was selected for further development and was synthesized on a 2-kg scale from (S)-(+)-hydroxymethyl-γ-butyrolactone.
Patent
Compounds and methods for the treatment of inflammatory and immune disorders
TL;DR: In this paper, 2,5-Diaryl tetrahydrofurans, 1,3-diaryl cyclopentanes, 2,4-direl pyrrolidines, and 2.5-dimethyltetrahydrothiophenes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response.
Patent
Compounds and methods for treatment of asthma, allergy and inflammatory disorders
Ralph Scannell,Chatelain Pierre,Anna Toy-Palmer,Edmond Differding,James L. Ellis,Marie-Agnes Lassoie,Young Michelle,Xiong Cai,Sajjat Hussoin,Gurmit Grewal,Timothy A. Lewis +10 more
TL;DR: In this article, the authors presented a mixture of 1,4 substituted piperazines, 1, 4 substituted pipers, and 1-substituted, 4-alkylidenyl piperidines compounds for treating conditions with histamine and leukotriene components.